Rgenix

Rgenix is a privately held biotechnology company based in New York, New York. The company employs 10 people and has generated $5 million in revenue. Rgenix focuses on developing novel cancer therapies. Their research centers around identifying key pathways in cancer progression and developing drugs that target these pathways. Using a discovery platform developed by the company's founders at Rockefeller University, Rgenix has identified several promising targets for cancer treatment, including those that regulate the tumor microenvironment and cancer metabolism pathways. The company's lead therapy, RGX-104, is a small molecule immunotherapy designed to prevent tumors from evading the immune system. RGX-104 has received FDA Orphan Drug Designation for several types of solid tumors with high unmet medical need and began clinical trials in the fourth quarter of 2016. For more information about Rgenix and its therapies, please visit their website at rgenix.com.